ir.genocea.comABOUT GENOCEA — Genocea Biosciences

Main navigation About Platform Pipeline Investors Genoceans Contact Main navigation About Platform Pipeline Investors Genoceans Contact Investor Relations Overview Press Releases Events & Presentations Governance Highlights Management Team Board of Directors Committee Composition Contact the Board Financials & Filings Financials SEC Filings Annual Reports and proxies Quarterly Results Stock Info Stock Quote & Chart Historic Stock Lookup Analyst Coverage Contact Us Investors ABOUT GENOCEA Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights: GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. Stock Quote () Volume Day High Day Low May 8, 2020 2:21 PM EDT Copyright Nasdaq. Minimum 15 minutes delayed. Stock Chart Press Releases Genocea to Host KOL Symposium Highlighting GEN-011’s Potential to Transform T cell Therapy for Solid Tumors May 5, 2020 at 4:05 PM EDT Call scheduled for May 12th from 12:00 – 1:30 p.m. EDT CAMBRIDGE, Mass. , May 05, 2020 (GLOBE NEWSWIRE)Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and Genocea Provides First Quarter 2020 Corporate Update April 30, 2020 at 7:00 AM EDT Clinical stage programs GEN-009 and GEN-011 continue to advance Anticipate GEN-011 IND filing in Q2 Expect GEN-009 Phase 1/2a Part B readout in Q3 GEN-011 Virtual Symposium planned for May 12 th Conference call today at 8:30 a.m. EDT CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE)Genocea Genocea to Host First Quarter 2020 Corporate Update Conference Call & Webcast April 23, 2020 at 8:01 PM EDT Virtual KOL symposium scheduled for May 12th to review GEN-011 – neoantigen T cell therapy – and the evolving T cell therapy landscape CAMBRIDGE, Mass. , April 23, 2020 (GLOBE NEWSWIRE)Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen View all news headlines Shareholder Tools Print Page Email Alerts Contact Us RSS News Feeds Search Site - Footer1 About Corporate Overview Management Team Board of Directors Scientific Advisory Board Platform ATLAS Platform Presentations and Publications Pipeline GEN-009 Partnering With Genocea Site - Footer 2 Investors Overview Press Releases Events & Presentations Corporate Governance Financial Filings Stock Information Genoceans Mission Statement Core Values Genoceans at Work Genoceans at Play Become a Genocean Site - Footer3 Contact Genocea 100 Acorn Park Dr Cambridge, MA 02140 Phone: 617.876.8191 Fax: 617.500.0969 CONNECT WITH US TERMS OF USEGenocea Biosciences, Inc. Copyright ©...